Cost of Revenue: Key Insights for Gilead Sciences, Inc. and Galapagos NV

Cost of Revenue: A Tale of Two Biotech Giants

In the ever-evolving biotech industry, understanding cost structures is crucial. Gilead Sciences, Inc. and Galapagos NV, two prominent players, offer a fascinating study in contrasts. From 2014 to 2023, Gilead's cost of revenue consistently dwarfed that of Galapagos, averaging around 4.9 billion annually, peaking at 6.6 billion in 2021. This reflects Gilead's expansive operations and robust product pipeline. In contrast, Galapagos, with a more modest scale, saw its costs rise from 111 million in 2014 to a high of 524 million in 2020, before a dramatic drop in 2021. This fluctuation highlights Galapagos' strategic shifts and market challenges. The data underscores the diverse strategies and market dynamics shaping these biotech titans, offering investors and industry watchers valuable insights into their operational efficiencies and market positioning.

Key Insights

• Gilead's cost of revenue is consistently higher, reflecting its larger scale.
• Galapagos experienced significant cost fluctuations, indicating strategic shifts.